Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Higher prevalence of irritable bowel syndrome and greater gastrointestinal symptoms in obsessive-compulsive disorder.

Turna J, Grosman Kaplan K, Patterson B, Bercik P, Anglin R, Soreni N, Van Ameringen M.

J Psychiatr Res. 2019 Aug 13;118:1-6. doi: 10.1016/j.jpsychires.2019.08.004. [Epub ahead of print] Review.

PMID:
31437616
2.

Metabolomics reveals elevated urinary excretion of collagen degradation and epithelial cell turnover products in irritable bowel syndrome patients.

Yamamoto M, Pinto-Sanchez MI, Bercik P, Britz-McKibbin P.

Metabolomics. 2019 May 20;15(6):82. doi: 10.1007/s11306-019-1543-0.

PMID:
31111238
3.

Investigation of the Gut Microbiome in Patients with Schizophrenia and Clozapine-Induced Weight Gain: Protocol and Clinical Characteristics of First Patient Cohorts.

Gorbovskaya I, Kanji S, Liu JCW, MacKenzie NE, Agarwal SM, Marshe VS, Sriretnakumar V, Verdu EF, Bercik P, De Palma G, Hahn MK, Müller DJ.

Neuropsychobiology. 2019 Mar 29:1-8. doi: 10.1159/000494696. [Epub ahead of print]

PMID:
30928978
4.

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply.

Keshteli AH, Madsen KL, Mandal R, Boeckxstaens GE, Bercik P, De Palma G, Reed DE, Wishart D, Vanner S, Dieleman LA.

Aliment Pharmacol Ther. 2019 Apr;49(8):1088-1089. doi: 10.1111/apt.15200. No abstract available.

PMID:
30920043
5.

Duodenal bacterial proteolytic activity determines sensitivity to dietary antigen through protease-activated receptor-2.

Caminero A, McCarville JL, Galipeau HJ, Deraison C, Bernier SP, Constante M, Rolland C, Meisel M, Murray JA, Yu XB, Alaedini A, Coombes BK, Bercik P, Southward CM, Ruf W, Jabri B, Chirdo FG, Casqueiro J, Surette MG, Vergnolle N, Verdu EF.

Nat Commun. 2019 Mar 13;10(1):1198. doi: 10.1038/s41467-019-09037-9.

6.

Response to Letter by Moulton et al.

Narula N, Pinto-Sanchez MI, Calo NC, Ford AC, Bercik P, Reinisch W, Moayyedi P.

Inflamm Bowel Dis. 2019 Jul 17;25(8):e99. doi: 10.1093/ibd/izz035. No abstract available.

PMID:
30824939
7.

Lactobacilli Degrade Wheat Amylase Trypsin Inhibitors to Reduce Intestinal Dysfunction Induced by Immunogenic Wheat Proteins.

Caminero A, McCarville JL, Zevallos VF, Pigrau M, Yu XB, Jury J, Galipeau HJ, Clarizio AV, Casqueiro J, Murray JA, Collins SM, Alaedini A, Bercik P, Schuppan D, Verdu EF.

Gastroenterology. 2019 Jun;156(8):2266-2280. doi: 10.1053/j.gastro.2019.02.028. Epub 2019 Feb 22.

PMID:
30802444
8.

Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers.

Keshteli AH, Madsen KL, Mandal R, Boeckxstaens GE, Bercik P, De Palma G, Reed DE, Wishart D, Vanner S, Dieleman LA.

Aliment Pharmacol Ther. 2019 Mar;49(6):723-732. doi: 10.1111/apt.15141. Epub 2019 Jan 31.

PMID:
30706502
9.

Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel Disease.

Narula N, Pinto-Sanchez MI, Calo NC, Ford AC, Bercik P, Reinisch W, Moayyedi P.

Inflamm Bowel Dis. 2019 Jun 18;25(7):1255-1261. doi: 10.1093/ibd/izy385.

PMID:
30615113
10.

Small-Molecule Allosteric Triggers of Clostridium difficile Toxin B Auto-proteolysis as a Therapeutic Strategy.

Ivarsson ME, Durantie E, Huberli C, Huwiler S, Hegde C, Friedman J, Altamura F, Lu J, Verdu EF, Bercik P, Logan SM, Chen W, Leroux JC, Castagner B.

Cell Chem Biol. 2019 Jan 17;26(1):17-26.e13. doi: 10.1016/j.chembiol.2018.10.002. Epub 2018 Oct 25.

PMID:
30482680
11.

Characterization of Simultaneous Pressure Waves as Biomarkers for Colonic Motility Assessed by High-Resolution Colonic Manometry.

Chen JH, Parsons SP, Shokrollahi M, Wan A, Vincent AD, Yuan Y, Pervez M, Chen WL, Xue M, Zhang KK, Eshtiaghi A, Armstrong D, Bercik P, Moayyedi P, Greenwald E, Ratcliffe EM, Huizinga JD.

Front Physiol. 2018 Sep 20;9:1248. doi: 10.3389/fphys.2018.01248. eCollection 2018.

12.

Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome.

Barbara G, Grover M, Bercik P, Corsetti M, Ghoshal UC, Ohman L, Rajilić-Stojanović M.

Gastroenterology. 2019 Jan;156(1):46-58.e7. doi: 10.1053/j.gastro.2018.07.011. Epub 2018 Nov 28.

PMID:
30009817
13.

High salt diet exacerbates colitis in mice by decreasing Lactobacillus levels and butyrate production.

Miranda PM, De Palma G, Serkis V, Lu J, Louis-Auguste MP, McCarville JL, Verdu EF, Collins SM, Bercik P.

Microbiome. 2018 Mar 22;6(1):57. doi: 10.1186/s40168-018-0433-4.

14.

Reply.

Pinto Sanchez MI, Moayyedi P, Bercik P.

Gastroenterology. 2018 Feb;154(3):764-765. doi: 10.1053/j.gastro.2018.01.022. Epub 2018 Jan 17. No abstract available.

PMID:
29351832
15.

Proton pump inhibitors for functional dyspepsia.

Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P.

Cochrane Database Syst Rev. 2017 Nov 21;11:CD011194. doi: 10.1002/14651858.CD011194.pub3. Review.

16.

Impact of β2-1 fructan on faecal community change: results from a placebo-controlled, randomised, double-blinded, cross-over study in healthy adults.

Clarke ST, Brooks SPJ, Inglis GD, Yanke LJ, Green J, Petronella N, Ramdath DD, Bercik P, Green-Johnson JM, Kalmokoff M.

Br J Nutr. 2017 Sep;118(6):441-453. doi: 10.1017/S0007114517002318. Epub 2017 Sep 28.

PMID:
28954640
17.

Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome.

Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, Martin FP, Cominetti O, Welsh C, Rieder A, Traynor J, Gregory C, De Palma G, Pigrau M, Ford AC, Macri J, Berger B, Bergonzelli G, Surette MG, Collins SM, Moayyedi P, Bercik P.

Gastroenterology. 2017 Aug;153(2):448-459.e8. doi: 10.1053/j.gastro.2017.05.003. Epub 2017 May 5.

18.

Safety of Adding Oats to a Gluten-Free Diet for Patients With Celiac Disease: Systematic Review and Meta-analysis of Clinical and Observational Studies.

Pinto-Sánchez MI, Causada-Calo N, Bercik P, Ford AC, Murray JA, Armstrong D, Semrad C, Kupfer SS, Alaedini A, Moayyedi P, Leffler DA, Verdú EF, Green P.

Gastroenterology. 2017 Aug;153(2):395-409.e3. doi: 10.1053/j.gastro.2017.04.009. Epub 2017 Apr 18. Review.

19.

Editorial: latent class analysis to improve confidence in the diagnosis of IBS - authors' reply.

Sood R, Gracie DJ, Gold MJ, To N, Pinto-Sanchez MI, Bercik P, Moayyedi P, Ford AC, Law GR.

Aliment Pharmacol Ther. 2017 May;45(9):1268-1269. doi: 10.1111/apt.14012. No abstract available.

20.

Letter: NICE referral criteria for lower gastrointestinal alarm features - not ideal but not poor either. Authors' reply.

Simpkins SJ, Pintos-Sanchez MI, Moayyedi P, Bercik P, Morgan DG, Bolino C, Ford AC.

Aliment Pharmacol Ther. 2017 Apr;45(8):1176. doi: 10.1111/apt.13996. No abstract available.

21.

Proton pump inhibitors for functional dyspepsia.

Pinto-Sanchez MI, Yuan Y, Bercik P, Moayyedi P.

Cochrane Database Syst Rev. 2017 Mar 8;3:CD011194. doi: 10.1002/14651858.CD011194.pub2. Review. Update in: Cochrane Database Syst Rev. 2017 Nov 21;11:CD011194.

22.

Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice.

De Palma G, Lynch MD, Lu J, Dang VT, Deng Y, Jury J, Umeh G, Miranda PM, Pigrau Pastor M, Sidani S, Pinto-Sanchez MI, Philip V, McLean PG, Hagelsieb MG, Surette MG, Bergonzelli GE, Verdu EF, Britz-McKibbin P, Neufeld JD, Collins SM, Bercik P.

Sci Transl Med. 2017 Mar 1;9(379). pii: eaaf6397. doi: 10.1126/scitranslmed.aaf6397.

PMID:
28251905
23.

Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysis.

Sood R, Gracie DJ, Gold MJ, To N, Pinto-Sanchez MI, Bercik P, Moayyedi P, Ford AC, Law GR.

Aliment Pharmacol Ther. 2017 Mar;45(6):824-832. doi: 10.1111/apt.13949. Epub 2017 Jan 20.

24.

Minimal differences in prevalence and spectrum of organic disease at upper gastrointestinal endoscopy between selected secondary care patients with symptoms of gastro-oesophageal reflux or dyspepsia.

Irvine AJ, Pinto-Sanchez MI, Bercik P, Moayyedi P, Ford AC.

Scand J Gastroenterol. 2017 Apr;52(4):396-402. doi: 10.1080/00365521.2016.1267792. Epub 2016 Dec 15.

25.

Poor predictive value of lower gastrointestinal alarm features in the diagnosis of colorectal cancer in 1981 patients in secondary care.

Simpkins SJ, Pinto-Sanchez MI, Moayyedi P, Bercik P, Morgan DG, Bolino C, Ford AC.

Aliment Pharmacol Ther. 2017 Jan;45(1):91-99. doi: 10.1111/apt.13846. Epub 2016 Nov 3.

26.

Acetylcholine-producing T cells in the intestine regulate antimicrobial peptide expression and microbial diversity.

Dhawan S, De Palma G, Willemze RA, Hilbers FW, Verseijden C, Luyer MD, Nuding S, Wehkamp J, Souwer Y, de Jong EC, Seppen J, van den Wijngaard RM, Wehner S, Verdu E, Bercik P, de Jonge WJ.

Am J Physiol Gastrointest Liver Physiol. 2016 Nov 1;311(5):G920-G933. doi: 10.1152/ajpgi.00114.2016. Epub 2016 Aug 11.

27.

Bifidobacterium infantis NLS Super Strain Reduces the Expression of α-Defensin-5, a Marker of Innate Immunity, in the Mucosa of Active Celiac Disease Patients.

Pinto-Sánchez MI, Smecuol EC, Temprano MP, Sugai E, González A, Moreno ML, Huang X, Bercik P, Cabanne A, Vázquez H, Niveloni S, Mazure R, Mauriño E, Verdú EF, Bai JC.

J Clin Gastroenterol. 2017 Oct;51(9):814-817. doi: 10.1097/MCG.0000000000000687.

PMID:
27636409
28.

Altered Esophageal Mucosal Structure in Patients with Celiac Disease.

Pinto-Sánchez MI, Nachman FD, Fuxman C, Iantorno G, Hwang HJ, Ditaranto A, Costa F, Longarini G, Wang XY, Huang X, Vázquez H, Moreno ML, Niveloni S, Bercik P, Smecuol E, Mazure R, Bilder C, Mauriño EC, Verdu EF, Bai JC.

Can J Gastroenterol Hepatol. 2016;2016:1980686. doi: 10.1155/2016/1980686. Epub 2016 Feb 29.

29.

Capturing the diversity of the human gut microbiota through culture-enriched molecular profiling.

Lau JT, Whelan FJ, Herath I, Lee CH, Collins SM, Bercik P, Surette MG.

Genome Med. 2016 Jul 1;8(1):72. doi: 10.1186/s13073-016-0327-7.

30.

SHP-2 Phosphatase Prevents Colonic Inflammation by Controlling Secretory Cell Differentiation and Maintaining Host-Microbiota Homeostasis.

Coulombe G, Langlois A, De Palma G, Langlois MJ, McCarville JL, Gagné-Sanfaçon J, Perreault N, Feng GS, Bercik P, Boudreau F, Verdu EF, Rivard N.

J Cell Physiol. 2016 Nov;231(11):2529-40. doi: 10.1002/jcp.25407. Epub 2016 May 8.

31.

Tracking gastrointestinal transit of solids in aged rats as pharmacological models of chronic dysmotility.

Dalziel JE, Young W, Bercik P, Spencer NJ, Ryan LJ, Dunstan KE, Lloyd-West CM, Gopal PK, Haggarty NW, Roy NC.

Neurogastroenterol Motil. 2016 Aug;28(8):1241-51. doi: 10.1111/nmo.12824. Epub 2016 Mar 29.

PMID:
27028044
32.

β2-1 Fructan supplementation alters host immune responses in a manner consistent with increased exposure to microbial components: results from a double-blinded, randomised, cross-over study in healthy adults.

Clarke ST, Green-Johnson JM, Brooks SP, Ramdath DD, Bercik P, Avila C, Inglis GD, Green J, Yanke LJ, Selinger LB, Kalmokoff M.

Br J Nutr. 2016 May 28;115(10):1748-59. doi: 10.1017/S0007114516000908. Epub 2016 Mar 18.

PMID:
26987626
33.

FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial.

McIntosh K, Reed DE, Schneider T, Dang F, Keshteli AH, De Palma G, Madsen K, Bercik P, Vanner S.

Gut. 2017 Jul;66(7):1241-1251. doi: 10.1136/gutjnl-2015-311339. Epub 2016 Mar 14. Erratum in: Gut. 2019 Jul;68(7):1342.

PMID:
26976734
34.

Lost in Translation: The Gut Microbiota in Psychiatric Illness.

Anglin R, Surette M, Moayyedi P, Bercik P.

Can J Psychiatry. 2015 Oct;60(10):460-3. No abstract available.

35.

Gluten Introduction to Infant Feeding and Risk of Celiac Disease: Systematic Review and Meta-Analysis.

Pinto-Sánchez MI, Verdu EF, Liu E, Bercik P, Green PH, Murray JA, Guandalini S, Moayyedi P.

J Pediatr. 2016 Jan;168:132-43.e3. doi: 10.1016/j.jpeds.2015.09.032. Epub 2015 Oct 21. Review. Erratum in: J Pediatr. 2016 Feb;169:331.

PMID:
26500108
36.

Microbiota and host determinants of behavioural phenotype in maternally separated mice.

De Palma G, Blennerhassett P, Lu J, Deng Y, Park AJ, Green W, Denou E, Silva MA, Santacruz A, Sanz Y, Surette MG, Verdu EF, Collins SM, Bercik P.

Nat Commun. 2015 Jul 28;6:7735. doi: 10.1038/ncomms8735.

PMID:
26218677
37.

Ecobiotherapy Rich in Firmicutes Decreases Susceptibility to Colitis in a Humanized Gnotobiotic Mouse Model.

Natividad JM, Pinto-Sanchez MI, Galipeau HJ, Jury J, Jordana M, Reinisch W, Collins SM, Bercik P, Surette MG, Allen-Vercoe E, Verdu EF.

Inflamm Bowel Dis. 2015 Aug;21(8):1883-93. doi: 10.1097/MIB.0000000000000422.

PMID:
26060932
38.

Anxiety and Depression Increase in a Stepwise Manner in Parallel With Multiple FGIDs and Symptom Severity and Frequency.

Pinto-Sanchez MI, Ford AC, Avila CA, Verdu EF, Collins SM, Morgan D, Moayyedi P, Bercik P.

Am J Gastroenterol. 2015 Jul;110(7):1038-48. doi: 10.1038/ajg.2015.128. Epub 2015 May 12.

PMID:
25964226
39.

No increase in prevalence of somatization in functional vs organic dyspepsia: a cross-sectional survey.

Gracie DJ, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P, Ford AC.

Neurogastroenterol Motil. 2015 Jul;27(7):1024-31. doi: 10.1111/nmo.12578. Epub 2015 Apr 30.

40.

Motility alterations in celiac disease and non-celiac gluten sensitivity.

Pinto-Sanchez MI, Bercik P, Verdu EF.

Dig Dis. 2015;33(2):200-7. doi: 10.1159/000371400. Epub 2015 Apr 22. Review.

PMID:
25925923
41.

Extraintestinal manifestations of celiac disease.

Pinto-Sánchez MI, Bercik P, Verdu EF, Bai JC.

Dig Dis. 2015;33(2):147-54. doi: 10.1159/000369541. Epub 2015 Apr 22. Review.

PMID:
25925916
42.

Lack of utility of symptoms and signs at first presentation as predictors of inflammatory bowel disease in secondary care.

Ford AC, Moayyedi P, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Reinisch W.

Am J Gastroenterol. 2015 May;110(5):716-24. doi: 10.1038/ajg.2015.117. Epub 2015 Apr 28.

43.

Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model.

Martín R, Miquel S, Chain F, Natividad JM, Jury J, Lu J, Sokol H, Theodorou V, Bercik P, Verdu EF, Langella P, Bermúdez-Humarán LG.

BMC Microbiol. 2015 Mar 21;15:67. doi: 10.1186/s12866-015-0400-1.

44.

Deciphering the pathogenesis of NSAID enteropathy using proton pump inhibitors and a hydrogen sulfide-releasing NSAID.

Blackler RW, De Palma G, Manko A, Da Silva GJ, Flannigan KL, Bercik P, Surette MG, Buret AG, Wallace JL.

Am J Physiol Gastrointest Liver Physiol. 2015 Jun 15;308(12):G994-1003.

45.

Tax-deductible provisions for gluten-free diet in Canada compared with systems for gluten-free diet coverage available in various countries.

Pinto-Sanchez MI, Verdu EF, Gordillo MC, Bai JC, Birch S, Moayyedi P, Bercik P.

Can J Gastroenterol Hepatol. 2015 Mar;29(2):104-10. Review.

46.

Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.

Leffler DA, Kelly CP, Green PH, Fedorak RN, DiMarino A, Perrow W, Rasmussen H, Wang C, Bercik P, Bachir NM, Murray JA.

Gastroenterology. 2015 Jun;148(7):1311-9.e6. doi: 10.1053/j.gastro.2015.02.008. Epub 2015 Feb 13.

47.

Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey.

Patel P, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P, Ford AC.

Scand J Gastroenterol. 2015 Jul;50(7):816-23. doi: 10.3109/00365521.2015.1007079. Epub 2015 Jan 30.

PMID:
25636675
48.

Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating.

Patel P, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P, Ford AC.

Aliment Pharmacol Ther. 2015 Mar;41(5):449-58. doi: 10.1111/apt.13074. Epub 2015 Jan 14.

49.

NSAID enteropathy and bacteria: a complicated relationship.

Syer SD, Blackler RW, Martin R, de Palma G, Rossi L, Verdu E, Bercik P, Surette MG, Aucouturier A, Langella P, Wallace JL.

J Gastroenterol. 2015 Apr;50(4):387-93. doi: 10.1007/s00535-014-1032-1. Epub 2015 Jan 10. Review.

PMID:
25572030
50.

Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota.

Blackler RW, Motta JP, Manko A, Workentine M, Bercik P, Surette MG, Wallace JL.

Br J Pharmacol. 2015 Feb;172(4):992-1004. doi: 10.1111/bph.12961. Epub 2014 Nov 24.

Supplemental Content

Loading ...
Support Center